DEERFIELD PARTNERS, L.P.
CIK 1301041 · last filed 2025-08-04
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$54.28M
Companies
14
Total Filings
19
Lifetime Open-Market Net
$424.90M
Filer Profile
Reported Address
345 PARK AVENUE SOUTH12TH FLOOR
NEW YORK, NY 10010
Phone
(212) 551-1600
State of Incorporation
DE
Formerly Known As
DEERFIELD PARTNERS, LP (2004–2016)
Related Filers
Deerfield Mgmt L.P. — 199 joint filings, latest 2026-07-17
DEERFIELD MANAGEMENT COMPANY, L.P. — 197 joint filings, latest 2026-07-17
James E Flynn — 196 joint filings, latest 2026-07-17
Deerfield Special Situations Fund, L.P. — 94 joint filings, latest 2019-10-30
DEERFIELD INTERNATIONAL LTD — 59 joint filings, latest 2011-06-07
Deerfield International Master Fund, L.P. — 58 joint filings, latest 2017-12-04
Deerfield Special Situations Fund International LTD — 39 joint filings, latest 2011-06-07
Deerfield Mgmt III, L.P. — 28 joint filings, latest 2026-03-02
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses.
View filings on SEC EDGAR.
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| LRMR | Director | 9,538,945 | $3.92 | $37.39M | $300.00M | 1 | 2025-08-04 |
| HOWL | 10%+ Owner | 1,752,787 | $0.98 | $1.72M | $51.20M | 1 | 2021-05-04 |
| NKTX | 10%+ Owner | 709,936 | $2.91 | $2.07M | $108.00M | 1 | 2020-07-14 |
| Generation Bio Co. (GBIO) Delisted | 10%+ Owner | 96,122 | $5.34 | $513.3K | $17.10M | 1 | 2020-06-16 |
| ACRS | 10%+ Owner | 1,411,628 | $5.32 | $7.51M | $0 | 2 | 2019-01-02 |
| CBIO | 10%+ Owner | 20,568 | $19.41 | $399.2K | -$10.96M | 1 | 2018-03-21 |
| Societal CDMO, Inc. (REPH) Delisted | 10%+ Owner | 1,287,132 | $2.09 | $2.69M | -$2.66M | 1 | 2017-06-09 |
| VNDA | 10%+ Owner | 850,778 | $5.09 | $4.33M | -$111.36M | 1 | 2016-09-26 |
| EHTH | 10%+ Owner | 923,448 | $0.93 | $860.7K | -$9.19M | 3 | 2016-06-16 |
| ANTARES PHARMA, INC. (ATRS) Delisted | 10%+ Owner | 8,268,733 | $5.59 | $46.22M | -$8.67M | 1 | 2015-07-08 |
| AUXILIUM PHARMACEUTICALS INC (AUXL) Delisted | 10%+ Owner | — | — | — | $0 | 1 | 2014-10-01 |
| Loxo Oncology, Inc. (LOXO) Delisted | 10%+ Owner | 469,470 | — | — | $99.21M | 1 | 2014-08-06 |
| MEDICINES CO /DE (MDCO) Delisted | 10%+ Owner | 3,475,538 | — | — | $0 | 1 | 2010-10-19 |
| NxStage Medical, Inc. (NXTM) Delisted | 10%+ Owner | 284,213 | — | — | -$7.77M | 2 | 2009-12-10 |
Recent Filings · Page 2 of 2
19 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2016-06-16 | EHTH | Sell (S) | −259,800 | -$3.61M | EDGAR |
| 2015-07-08 | ANTARES PHARMA, INC. (ATRS) Delisted | Sell (S) | −4,172,525 | -$8.67M | EDGAR |
| 2015-03-09 | EHTH | Sell (S) | −4,027,719 | -$38.34M | EDGAR |
| 2014-10-01 | AUXILIUM PHARMACEUTICALS INC (AUXL) Delisted | Sell (S) | — | $0 | EDGAR |
| 2014-08-06 | Loxo Oncology, Inc. (LOXO) Delisted | Mixed | +11,140,822 | $99.21M | EDGAR |
| 2014-08-05 | EHTH | Buy (P) | +1,647,700 | $32.76M | EDGAR |
| 2010-10-19 | MEDICINES CO /DE (MDCO) Delisted | Exer (X) | +2,660,500 | $31.62M | EDGAR |
| 2009-12-10 | NxStage Medical, Inc. (NXTM) Delisted | Sell (S) | −490,914 | -$3.62M | EDGAR |
| 2009-09-21 | NxStage Medical, Inc. (NXTM) Delisted | Sell (S) | −616,140 | -$4.15M | EDGAR |
Showing 11–19 of 19
Prev
Page 2 of 2
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.